ijms-logo

Journal Browser

Journal Browser

DNA Damage and DNA Repair Pathways in Cancer Development

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 520

Special Issue Editor


E-Mail Website
Guest Editor
Department of Diagnostic Pathology, Kindai University Hospital, Osaka 589-8511, Japan
Interests: transcription-coupled DNA damage; lymphomagenesis; mRNA export; breast carcinogenesis; antibody engineering
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

DNA lesions produced by a variety of genotoxic stresses are precisely repaired to avoid the genomic instability which is associated with a high predisposition to cancer development. The occurrence of unrepaired DNA lesions is censored by DNA-damage response (DDR) composed of complex cascades followed by the induction of cell-cycle arrest or apoptosis. As most tumors show impaired DDR, many studies have focused on the understanding of detailed molecular mechanisms in DDR-pathways and/or cancer-related DNA repair defects to reveal the cause of cancers. In addition, this information has provided us new therapeutic targets. Recently, when the germ-line mutations exist in breast cancers, PARP inhibitors offer a new therapeutic option based on the concept of synthetic lethality. Moreover, it is known that various inhibitors targeting molecules associated with DDR are in clinical trials. Comprehensive analyses of canonical and non-canonical DNA repair pathways and the interactions of each molecule defective in various cancers are promising to search for potential therapeutic targets. Therefore, authors are invited to submit original research and review articles that address the physiological, pathophysiological, pharmacological, and epidemiological importance of DDR and/or DNA repair pathways in cancer development.

Topics include, but are not limited to:

  • Involvement of canonical or non-canonical DNA repair pathways in cancer development;
  • Identification of the novel therapeutic targets in DNA repair pathway;
  • Animal models mimicking the development of various human cancers;
  • Pathological significance of aberrantly expressed DNA repair-related molecules in human clinical samples.

Dr. Kazuhiko Kuwahara
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • DNA-damage response
  • DNA repair molecules
  • genome instability
  • cellular senescence
  • animal models
  • DNA damage
  • DNA repair and cancer

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 2261 KiB  
Article
Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models
by Steffie Revia, Felix Neumann, Julia Jabs, Florian Orio, Christian Sirrenberg, Astrid Zimmermann, Christiane Amendt and Joachim Albers
Int. J. Mol. Sci. 2024, 25(10), 5120; https://doi.org/10.3390/ijms25105120 - 8 May 2024
Viewed by 263
Abstract
Triple-negative breast cancer (TNBC) remains the most lethal subtype of breast cancer, characterized by poor response rates to current chemotherapies and a lack of additional effective treatment options. While approximately 30% of patients respond well to anthracycline- and taxane-based standard-of-care chemotherapy regimens, the [...] Read more.
Triple-negative breast cancer (TNBC) remains the most lethal subtype of breast cancer, characterized by poor response rates to current chemotherapies and a lack of additional effective treatment options. While approximately 30% of patients respond well to anthracycline- and taxane-based standard-of-care chemotherapy regimens, the majority of patients experience limited improvements in clinical outcomes, highlighting the critical need for strategies to enhance the effectiveness of anthracycline/taxane-based chemotherapy in TNBC. In this study, we report on the potential of a DNA-PK inhibitor, peposertib, to improve the effectiveness of topoisomerase II (TOPO II) inhibitors, particularly anthracyclines, in TNBC. Our in vitro studies demonstrate the synergistic antiproliferative activity of peposertib in combination with doxorubicin, epirubicin and etoposide in multiple TNBC cell lines. Downstream analysis revealed the induction of ATM-dependent compensatory signaling and p53 pathway activation under combination treatment. These in vitro findings were substantiated by pronounced anti-tumor effects observed in mice bearing subcutaneously implanted tumors. We established a well-tolerated preclinical treatment regimen combining peposertib with pegylated liposomal doxorubicin (PLD) and demonstrated strong anti-tumor efficacy in cell-line-derived and patient-derived TNBC xenograft models in vivo. Taken together, our findings provide evidence that co-treatment with peposertib has the potential to enhance the efficacy of anthracycline/TOPO II-based chemotherapies, and it provides a promising strategy to improve treatment outcomes for TNBC patients. Full article
(This article belongs to the Special Issue DNA Damage and DNA Repair Pathways in Cancer Development)
Show Figures

Figure 1

Back to TopTop